The Division of Surgical Oncology is dedicated to providing state of the art multidisciplinary treatment to cancer patients. Our clinical programs are carefully integrated into the clinical programs in medical oncology, radiation oncology and medical imaging. Individual cases are discussed at multidisciplinary conference to ensure that patients receive the optimum sequence of the various therapies designed to eradicate cancer. The division participates in a number of clinical trials designed to utilize the latest technology in the treatment of human malignancy.
The breast program participates in various trials. Sentinel lymph node technology is used to reduce the number of patients that require a full lymph node dissection. Physicians within the division are active participants in the NSABP trials including the STAR trial which examines the role of selective estrogen response modifiers in the treatment of breast cancer prevention. We are active participants in the American College of Surgeon Oncology Group Breast Cancer Trials (Z10, Z11), which are designed to reduce the amount of surgery required for the treatment of breast cancer. We also have an active risk assessment program that was developed by Dr. Euhus. This computer generated program evaluates an individual patient’s life time risk for developing breast cancer so that appropriate interventions may be initiated to reduce the risk We also have an active program for the treatment of lymphedema.
The melanoma program involves close interaction with the Department of Dermatology and Medical Oncology. UTSW is a site of an immunotherapy trial for the treatment of patients with high risk melanoma. This trial studies the ability of a whole cell melanoma vaccine to prevent recurrence of melanoma in patients following surgery. In addition, the use of Positron Emission Tomography (PET) scanning is being investigated as a method for early detection of distant metastases in this disease.
The program in pancreatic and hepatobiliary cancer is directed by Dr. Carlton C. Barnett, Jr. This program works closely with Medical Oncology, Radiation Oncology, Radiology and Gastroenterology to develop new methods for treating these highly fatal cancers. Several multidisciplinary trials using various combinations of radiation therapy and novel chemotherapeutic agents are underway for patients with pancreatic cancer. Patients with primary or secondary liver tumors are now treated with a variety of new techniques including Radiofrequency ablation (RFA), chemoembolization, and hepatic artery infusion.
The program in colorectal cancer is directed by Dr. Thomas Anthony. Working closely with medical oncology and radiation oncology, this group is looking at the sequencing of chemotherapy and radiation therapy in the treatment of rectal cancer. In addition, they are involved in quality of life assessment in patients undergoing treatment for colon cancer.
An active program has also been established for the treatment of Soft Tissue Sarcomas. Emphasis is placed upon proper timing of chemotherapy and radiation therapy with respect to surgical resection. Tumor markers which may provide valuable information regarding prognosis are also being investigated.
